Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
|---|---|---|---|---|---|
| GMP-L12H23 | Human | GMP Human IL-12 Protein |
|
||
| IL2-H5210 | Human | Human IL-12 Protein, premium grade |
|
||
| IL2-H8210 | Human | Biotinylated Human IL-12B&IL-12A Heterodimer Protein, His,Avitag™&Flag Tag |  |
|
|
| IL2-H4210 | Human | Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (MALS verified) |  |
|
GMP Human IL-12 Protein (Cat. No. GMP-L12H23) stimulates secretion of IFN-γ by NK-92. The specific activity of GMP Human IL-12 Protein is > 1.00ⅹ10^7 IU/mg, which is calibrated against human IL-12 WHO International Standard (NIBSC code: 95/544) (QC tested).
Human IL-12 Protein, premium grade (Cat. No. IL2-H5210) stimulates secretion of IFN-γ by NK-92 human natural killer lymphoma cells. The specific activity of Human IL-12 Protein, premium grade is > 1.00ⅹ10^7 IU/mg, which is calibrated against human IL-12 WHO International Standard (NIBSC code: 95/544) (QC tested).
Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 2.06 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab | CNTO-1275; C-340 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Arthritis, Juvenile; Crohn Disease; Dermatitis, Atopic; Plaque psoriasis; Hidradenitis Suppurativa; Uveitis; Common Variable Immunodeficiency; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Liver Cirrhosis, Biliary; Multiple Sclerosis; Sjogren's Syndrome; Pouchitis; Ichthyosis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Diabetes Mellitus, Type 1; Polymyositis | Details |
| Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™ | Japan | Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Psoriasis; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease | Details |
| Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA | United States | Crohn Disease; Plaque psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
| Ustekinumab | CNTO-1275; C-340 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Arthritis, Juvenile; Crohn Disease; Dermatitis, Atopic; Plaque psoriasis; Hidradenitis Suppurativa; Uveitis; Common Variable Immunodeficiency; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Liver Cirrhosis, Biliary; Multiple Sclerosis; Sjogren's Syndrome; Pouchitis; Ichthyosis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Diabetes Mellitus, Type 1; Polymyositis | Details |
| Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™ | Japan | Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Psoriasis; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease | Details |
| Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA | United States | Crohn Disease; Plaque psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ustekinumab biosimilar (Bio-Thera ) | BAT-2206 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease | Details |
| Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Psoriasis | Details | |
| Lisofylline | BL-194; CT-1501R; A-802710 | Phase 3 Clinical | Cti Biopharma Corp | Diabetes Mellitus, Type 1; Rejection of organ transplantation | Details |
| Ustekinumab Biosimilar (qyuns) | QX-001-S; HDM-3001; QX-001S | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Psoriasis; Plaque psoriasis | Details |
| Ustekinumab Biosimilar(Celltrion) | CT-P43 | Phase 3 Clinical | Celltrion Inc | Psoriasis | Details |
| Ustekinumab biosimilar(Biocon) | Phase 3 Clinical | Biocon Biologics Ltd | Psoriasis | Details | |
| Ustekinumab biosimilar(CSPC Pharma) | SYSA-1902 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Psoriasis; Plaque psoriasis | Details |
| Apilimod mesilate | AIT-101; STA-5326-mesylate; LAM-002; STA-5326; LAM-002A | Phase 2 Clinical | Synta Pharmaceuticals Corp, Lam | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Common Variable Immunodeficiency; Crohn Disease; Amyotrophic Lateral Sclerosis | Details |
| NSC-733972 | M-032; M032-H SV-1; NSC-733972 | Phase 2 Clinical | University Of Alabama At Birmingham | Glioblastoma; Gliosarcoma; Astrocytoma | Details |
| Tavokinogene telseplasmid (OncoSec Medical) | pIL-12; DNA IL-12 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Hepatocellular; Mycosis Fungoides; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Colorectal Neoplasms; Breast Neoplasms; Hepatitis B; Prostatic Neoplasms; Small Cell Lung Carcinoma; Hemorrhagic Fever, Ebola; Pancreatic Neoplasms; Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| INO-9012/Human papillomavirus vaccine | INO-3112; INO-9012/VGX-3100; VGX-3100/INO-9012 | Phase 2 Clinical | University Of Pennsylvania, Astrazeneca Plc, Inovio Pharmaceuticals Inc | Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Vaginal Neoplasms; Papillomavirus Infections; Neoplasms; Carcinoma, Transitional Cell; Vulvar Neoplasms; Oropharyngeal Neoplasms; Penile Neoplasms; Uterine Cervical Neoplasms | Details |
| T-3011 | T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015 | Phase 2 Clinical | Immvira Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Squamous Cell; Lymphoma; Endometrial Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Sarcoma; Liver Neoplasms; Ascites; Mesothelioma; Small Cell Lung Carcinoma; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
| PDS-0301 | M-9241; MSB-0010360; MSB0010360; PDS-0301 | Phase 2 Clinical | Emd Serono Inc, Merck Serono, National Cancer Institute | Prostatic Neoplasms; Sarcoma, Kaposi; Uterine Cervical Neoplasms; Urogenital Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Cholangiocarcinoma; Vulvar Neoplasms; Intestinal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Papillomavirus Infections; Rectal Neoplasms; Carcinoma; Anus Neoplasms | Details |
| STX-001 | STX-001 | Phase 2 Clinical | Massachusetts Institute Of Technology | Solid tumours | Details |
| DF-6002 | DF-6002 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours; Neoplasms | Details |
| Recombinant Human nsIL12 Oncolytic Adenovirus (Beijing Haute Biotechnology) | BioTTT-001; BioTTT001 | Phase 2 Clinical | Beijing Bio-Targeting Therapeutics Technology Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms | Details |
| Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) | VG-161 | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Solid tumours; Liver Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Sarcoma; Cholangiocarcinoma; Carcinoma, Hepatocellular | Details |
| Rocakinogene sifuplasmid | INO-9012 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Urogenital Abnormalities; Carcinoma, Hepatocellular; Precancerous Conditions; Lung Neoplasms; Vulvar Diseases; Hepatitis C; Colorectal Neoplasms; Squamous Intraepithelial Lesions of the Cervix; Breast Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Transitional Cell; Liver Neoplasms; Neoplasms, Glandular and Epithelial; Papillomavirus Infections; Pancreatic Neoplasms; Glioblastoma; Esophageal Neoplasms; Stomach Neoplasms; Hemorrhagic Fever, Ebola; Hepatitis, Chronic; Head and Neck Neoplasms; HIV Infections; Ovarian Neoplasms | Details |
| Veledimex | INXN-1001; AD-1001 | Phase 1 Clinical | Ziopharm Oncology Inc | Glioblastoma; Brain Neoplasms; Breast Neoplasms; Astrocytoma; Diffuse Intrinsic Pontine Glioma; Melanoma | Details |
| XTX-301 | XTX-301 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
| VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | ViroGin Biotech Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, Fenojian Biotechnology (Nantong) Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Breast Neoplasms | Details |
| MVR-C5252 | C-5252; MVR-C5252 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms; Glioma | Details |
| WTX-330 | WTX-330 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin | Details |
| WTX-124 | WTX-124 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasm Metastasis | Details |
| IL-12 DNA(NIAID) | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| SW-0715 | SW-0715 | Phase 1 Clinical | Stemirna Therapeutics | Solid tumours | Details |
| KGX-101 | KGX-101; KGX101; KGX-101(IL-12-Fc融合蛋白); KGX-101(改造优化的细胞因子IL12前药分子) | Phase 1 Clinical | Shanghai KangaBio Co Ltd | Solid tumours; Neoplasms | Details |
| Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
| TG-6050 | TG-6050 | Phase 1 Clinical | Transgene Sa | Carcinoma, Non-Small-Cell Lung | Details |
| Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
| ABOD-2011 | ABOD-2011 | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Solid tumours | Details |
| JCXH-211 | JCXH-211 | Phase 1 Clinical | Jiachen Xihai(Hangzhou)Biotechnology Co Ltd | Solid tumours; Skin Neoplasms | Details |
| EGFR IL12 CART | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Colorectal Neoplasms | Details | |
| XmAb-662 | XmAb-662 | Phase 1 Clinical | Xencor Inc | Solid tumours; Neoplasms | Details |
| MEDI-1191 | MEDI-1191; MEDI1191 | Phase 1 Clinical | Moderna Inc | Solid tumours; Neoplasms | Details |
| Ustekinumab biosimilar (BioFactura) | BFI-751 | Phase 1 Clinical | BioFactura Australia Pty Ltd | Psoriasis | Details |
| MEDI-9253 | Phase 1 Clinical | Astrazeneca Plc | Solid tumours; Neoplasms | Details | |
| INXN-2001 | Ad-IL-12; ZIN-ATI-001; Ad-RTS-hIL-12; Ad-RTS-mIL-12; INXN-2001; Ad-RTS-IL-12; INXN-2001 (Ad-RTS-IL-12) | Phase 1 Clinical | Ziopharm Oncology Inc | Glioblastoma; Breast Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma; Astrocytoma; Melanoma | Details |
| Ustekinumab biosimilar (Bio-Thera ) | BAT-2206 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease | Details |
| Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Psoriasis | Details | |
| Lisofylline | BL-194; CT-1501R; A-802710 | Phase 3 Clinical | Cti Biopharma Corp | Diabetes Mellitus, Type 1; Rejection of organ transplantation | Details |
| Ustekinumab Biosimilar (qyuns) | QX-001-S; HDM-3001; QX-001S | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Psoriasis; Plaque psoriasis | Details |
| Ustekinumab Biosimilar(Celltrion) | CT-P43 | Phase 3 Clinical | Celltrion Inc | Psoriasis | Details |
| Ustekinumab biosimilar(Biocon) | Phase 3 Clinical | Biocon Biologics Ltd | Psoriasis | Details | |
| Ustekinumab biosimilar(CSPC Pharma) | SYSA-1902 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Psoriasis; Plaque psoriasis | Details |
| Apilimod mesilate | AIT-101; STA-5326-mesylate; LAM-002; STA-5326; LAM-002A | Phase 2 Clinical | Synta Pharmaceuticals Corp, Lam | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Common Variable Immunodeficiency; Crohn Disease; Amyotrophic Lateral Sclerosis | Details |
| NSC-733972 | M-032; M032-H SV-1; NSC-733972 | Phase 2 Clinical | University Of Alabama At Birmingham | Glioblastoma; Gliosarcoma; Astrocytoma | Details |
| Tavokinogene telseplasmid (OncoSec Medical) | pIL-12; DNA IL-12 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Hepatocellular; Mycosis Fungoides; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Colorectal Neoplasms; Breast Neoplasms; Hepatitis B; Prostatic Neoplasms; Small Cell Lung Carcinoma; Hemorrhagic Fever, Ebola; Pancreatic Neoplasms; Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| INO-9012/Human papillomavirus vaccine | INO-3112; INO-9012/VGX-3100; VGX-3100/INO-9012 | Phase 2 Clinical | University Of Pennsylvania, Astrazeneca Plc, Inovio Pharmaceuticals Inc | Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Vaginal Neoplasms; Papillomavirus Infections; Neoplasms; Carcinoma, Transitional Cell; Vulvar Neoplasms; Oropharyngeal Neoplasms; Penile Neoplasms; Uterine Cervical Neoplasms | Details |
| T-3011 | T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015 | Phase 2 Clinical | Immvira Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Squamous Cell; Lymphoma; Endometrial Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Sarcoma; Liver Neoplasms; Ascites; Mesothelioma; Small Cell Lung Carcinoma; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
| PDS-0301 | M-9241; MSB-0010360; MSB0010360; PDS-0301 | Phase 2 Clinical | Emd Serono Inc, Merck Serono, National Cancer Institute | Prostatic Neoplasms; Sarcoma, Kaposi; Uterine Cervical Neoplasms; Urogenital Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Cholangiocarcinoma; Vulvar Neoplasms; Intestinal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Papillomavirus Infections; Rectal Neoplasms; Carcinoma; Anus Neoplasms | Details |
| STX-001 | STX-001 | Phase 2 Clinical | Massachusetts Institute Of Technology | Solid tumours | Details |
| DF-6002 | DF-6002 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours; Neoplasms | Details |
| Recombinant Human nsIL12 Oncolytic Adenovirus (Beijing Haute Biotechnology) | BioTTT-001; BioTTT001 | Phase 2 Clinical | Beijing Bio-Targeting Therapeutics Technology Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms | Details |
| Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) | VG-161 | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Solid tumours; Liver Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Sarcoma; Cholangiocarcinoma; Carcinoma, Hepatocellular | Details |
| Rocakinogene sifuplasmid | INO-9012 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Urogenital Abnormalities; Carcinoma, Hepatocellular; Precancerous Conditions; Lung Neoplasms; Vulvar Diseases; Hepatitis C; Colorectal Neoplasms; Squamous Intraepithelial Lesions of the Cervix; Breast Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Transitional Cell; Liver Neoplasms; Neoplasms, Glandular and Epithelial; Papillomavirus Infections; Pancreatic Neoplasms; Glioblastoma; Esophageal Neoplasms; Stomach Neoplasms; Hemorrhagic Fever, Ebola; Hepatitis, Chronic; Head and Neck Neoplasms; HIV Infections; Ovarian Neoplasms | Details |
| Veledimex | INXN-1001; AD-1001 | Phase 1 Clinical | Ziopharm Oncology Inc | Glioblastoma; Brain Neoplasms; Breast Neoplasms; Astrocytoma; Diffuse Intrinsic Pontine Glioma; Melanoma | Details |
| XTX-301 | XTX-301 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
| VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | ViroGin Biotech Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, Fenojian Biotechnology (Nantong) Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Breast Neoplasms | Details |
| MVR-C5252 | C-5252; MVR-C5252 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms; Glioma | Details |
| WTX-330 | WTX-330 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin | Details |
| WTX-124 | WTX-124 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasm Metastasis | Details |
| IL-12 DNA(NIAID) | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| SW-0715 | SW-0715 | Phase 1 Clinical | Stemirna Therapeutics | Solid tumours | Details |
| KGX-101 | KGX-101; KGX101; KGX-101(IL-12-Fc融合蛋白); KGX-101(改造优化的细胞因子IL12前药分子) | Phase 1 Clinical | Shanghai KangaBio Co Ltd | Solid tumours; Neoplasms | Details |
| Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
| TG-6050 | TG-6050 | Phase 1 Clinical | Transgene Sa | Carcinoma, Non-Small-Cell Lung | Details |
| Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
| ABOD-2011 | ABOD-2011 | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Solid tumours | Details |
| JCXH-211 | JCXH-211 | Phase 1 Clinical | Jiachen Xihai(Hangzhou)Biotechnology Co Ltd | Solid tumours; Skin Neoplasms | Details |
| EGFR IL12 CART | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Colorectal Neoplasms | Details | |
| XmAb-662 | XmAb-662 | Phase 1 Clinical | Xencor Inc | Solid tumours; Neoplasms | Details |
| MEDI-1191 | MEDI-1191; MEDI1191 | Phase 1 Clinical | Moderna Inc | Solid tumours; Neoplasms | Details |
| Ustekinumab biosimilar (BioFactura) | BFI-751 | Phase 1 Clinical | BioFactura Australia Pty Ltd | Psoriasis | Details |
| MEDI-9253 | Phase 1 Clinical | Astrazeneca Plc | Solid tumours; Neoplasms | Details | |
| INXN-2001 | Ad-IL-12; ZIN-ATI-001; Ad-RTS-hIL-12; Ad-RTS-mIL-12; INXN-2001; Ad-RTS-IL-12; INXN-2001 (Ad-RTS-IL-12) | Phase 1 Clinical | Ziopharm Oncology Inc | Glioblastoma; Breast Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma; Astrocytoma; Melanoma | Details |
This web search service is supported by Google Inc.
A-Z
